IBRXImmunityBio Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Richard Adcock

Location

California, USA

Exchange

Nasdaq

Website

https://immunitybio.com

Summary

ImmunityBio, Inc.

Company Info

CEO

Richard Adcock

Location

California, USA

Exchange

Nasdaq

Website

https://immunitybio.com

Summary

ImmunityBio, Inc.

AI Insights for IBRX
5 min read

Quick Summary

ImmunityBio, Inc. is a San Diego-based biotechnology company focused on immunotherapy and cell therapy for cancer and infectious disease. The company has transitioned from a mainly clinical-stage profile toward a commercial-stage oncology business centered on ANKTIVA, its approved immunotherapy used with BCG for certain non-muscle invasive bladder cancer patients. Its platforms include antibody-cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cell therapies, CAR-NK approaches, and T-cell immune system technologies. Its main customers are oncology providers, urologists, hospitals, specialty pharmacies, cancer treatment centers, and healthcare systems that treat bladder cancer and other malignancies. The company also serves patients and payers in markets where ANKTIVA is approved or being launched, including the United States, Europe, Saudi Arabia, and other international jurisdictions. ImmunityBio remains highly dependent on successful clinical development, regulatory approvals, reimbursement access, physician adoption, and manufacturing execution.

Strengths

•

ImmunityBio’s biggest strength is that it now has a commercial oncology product with visible momentum rather than only a speculative pipeline.

•

ANKTIVA addresses a serious bladder cancer indication with meaningful unmet need and has gained approvals or authorizations across multiple jurisdictions.

•

The company’s technology base is broad, spanning cytokine fusion, NK-cell therapy, CAR-NK therapy, vaccines, and immune-system activation.

•

Recent patent grants extending ANKTIVA plus BCG protection to at least 2035 strengthen the company’s intellectual property position.

•

Strong investor sentiment, analyst Buy ratings, and multiple upcoming clinical and regulatory catalysts give the stock significant upside optionality.

Key Risks

•

The largest risk is clinical and regulatory failure, because ImmunityBio’s valuation depends heavily on successful expansion of ANKTIVA and progress across its oncology pipeline.

•

ANKTIVA revenue growth may not continue at the recent pace if physician adoption slows, payers restrict coverage, supply issues emerge, or competitors gain traction.

•

The company’s reliance on one primary commercial product makes it vulnerable to product-specific safety, efficacy, reimbursement, and market-access problems.

•

Losses and high R&D spending create financing risk, especially if cash needs rise or capital markets become less favorable for biotech companies.

What to Watch

During the most recent reported period, ImmunityBio continued to show the profile of a fast-growing but still loss-making biotech company.
The data set shows operating revenue of about $51.2 million, gross profit of about $50.9 million, and operating income of negative $61.7 million.
Recent news highlighted rapid ANKTIVA growth, including reports that 2025 sales reached about $113 million and that revenue rose sharply year over year.
The company received important regulatory progress, including European conditional marketing authorization for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ.
It also gained authorization to market ANKTIVA in Saudi Arabia and announced U.S. patents that extend protection for ANKTIVA plus BCG in bladder cancer to at least 2035.
Clinical updates for the CD19 CAR-NK program and bladder cancer enrollment progress were major investor events that helped trigger a sharp rally in the stock.

Price Drivers

•

IBRX’s stock price is being driven primarily by clinical trial news, ANKTIVA commercial momentum, regulatory approvals, and investor appetite for high-risk oncology biotech names.

•

Recent shares surged after strong updates for CD19 CAR-NK blood cancer therapy, reported rapid ANKTIVA revenue growth, and new international approvals.

•

The stock is also influenced by analyst price targets, short interest, patent announcements, reimbursement developments, and expectations for label expansion filings.

•

Fundamental valuation is a major factor because the company has a high enterprise-value-to-revenue ratio and remains unprofitable, with negative EPS and significant net losses.

•

The market is rewarding the possibility of rapid revenue scaling, but it can quickly punish delays, weak sales trends, trial disappointments, dilution, or regulatory setbacks.

•

Broader biotech sentiment, interest-rate expectations, oncology deal activity, and risk appetite for speculative growth stocks can also materially affect IBRX.

Recent News

•

Recent news about ImmunityBio has been unusually positive and has driven a major rally in IBRX shares.

•

The stock surged for multiple consecutive sessions after strong CD19 CAR-NK blood cancer therapy results, rapid ANKTIVA revenue growth, and approval to market ANKTIVA in Saudi Arabia.

•

The European Commission granted conditional marketing authorization for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, making it the first approved European therapy for that indication.

•

The company also received five U.S. patents for ANKTIVA plus BCG in non-muscle invasive bladder cancer, extending protection to at least 2035.

•

Analysts have maintained bullish ratings, with some price targets implying substantial upside, although they also acknowledge high risk.

•

News coverage has repeatedly emphasized the company’s transition into a commercial-stage biotech, its dependence on ANKTIVA, and the need to execute launches and clinical programs successfully.

Market Trends

•

The broader oncology market remains one of the most attractive areas in biotechnology because cancer therapies can command high prices and address major unmet medical needs.

•

Immuno-oncology continues to be a leading investment theme, but the market is increasingly competitive as checkpoint inhibitors, cell therapies, gene therapies, antibody therapies, and immune stimulators all compete for clinical relevance.

•

Bladder cancer is receiving significant innovation because many patients fail BCG or need better options after limited historical progress.

•

Cell therapy remains a powerful but risky market trend, with investors rewarding strong early efficacy while remaining cautious about manufacturing, toxicity, durability, and cost.

•

Biotech stocks are also sensitive to interest rates, funding conditions, FDA decisions, reimbursement policy, and investor willingness to take risk.

•

In this environment, ImmunityBio benefits from strong oncology demand and recent commercial traction, but it must prove that revenue growth and clinical success can support its valuation.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on IBRX

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Ok_West_5560 8 months ago

IBRX founder speaking at Cancer 2035 summit with NIH leaders

IBRX founder speaking at Cancer 2035 summit with NIH leaders

post thumbnail
avatar
@BarnaclesActiv 9 months ago

ImmunityBio (IBRX) partners with distributors to launch ANKTIVA in Saudi Arabia and MENA region

ImmunityBio (IBRX) partners with distributors to launch ANKTIVA in Saudi Arabia and MENA region

post thumbnail
avatar
@BarnaclesActiv 9 months ago

ImmunityBio (IBRX) meeting with Saudi FDA regarding rBCG and ANKTIVA expansion

ImmunityBio (IBRX) meeting with Saudi FDA regarding rBCG and ANKTIVA expansion

post thumbnail
avatar
@UndyingValue 10 months ago

ImmunityBio releases Phase 2 glioblastoma results, median survival not yet reached

ImmunityBio releases Phase 2 glioblastoma results, median survival not yet reached

post thumbnail
avatar
@democratiCrayn 10 months ago

IBRX receives ANKTIVA approval in Saudi Arabia

IBRX receives ANKTIVA approval in Saudi Arabia

post thumbnail
avatar
@democratiCrayn 11 months ago

Jefferies raises IBRX price target to $9 after European approval

Jefferies raises IBRX price target to $9 after European approval

post thumbnail

No more topics to show